BTZ showed encouraging in vitro activity against a panel of human NSCLC cell lines, even though NSCLC cells with aberrant apoptosis (increased Bcl-2) or high basal proteasome activity were intrinsically less sensitive to BTZ [29, 79]. The gene discussed is BCL2; the disease is non-small cell lung carcinoma.